Decreased HIV-associated T cell apoptosis by HIV protease inhibitors.

Antiretroviral treatment of patients infected with HIV results in improvements in CD4+ T cell number. Emerging evidence suggests that some of the improvements in CD4+ T cell number that occur in response to protease inhibitor (PI) therapy may not be accounted for solely by enhanced viral suppression, implying that PI may directly affect T cell survival. Since HIV T cell depletion is associated with enhanced apoptosis, we analyzed the effect of PIs on T cell apoptosis. In vitro treatment of peripheral blood lymphocytes (PBLs) from HIV-infected but untreated patients with reverse transcriptase inhibitors (RTIs) does not alter apoptosis, whereas PI treatment rapidly reduces CD4+ and CD8+ T cell apoptosis. In contrast, PI treatment does not alter apoptosis in PBL blasts from HIV-negative patients, or in Jurkat T cells. Consistent with this observation, 8 days of PI therapy in HIV-infected patients does not significantly alter plasma viremia, yet results in significant inhibition of CD4+ and CD8+ T cell apoptosis. The inhibitory effects of PI on apoptosis have implications concerning the treatment of HIV and its pathogenesis.

[1]  J. Corbeil,et al.  HIV‐induced apoptosis of activated primary CD4+ T lymphocytes is not mediated by Fas–Fas ligand , 1997, AIDS.

[2]  C. Flexner.  HIV-protease inhibitors. , 1998, The New England journal of medicine.

[3]  J. Kahn,et al.  Protease inhibitors do not increase the CD4+ cell count in HIV-uninfected individuals. , 1998, AIDS (London).

[4]  D. Margolis,et al.  Activation of CD8+ T lymphocytes through the T cell receptor turns on CD4 gene expression: implications for HIV pathogenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Douglas K. Miller,et al.  The role of the Caspase family of cysteine proteases in apoptosis. , 1997, Seminars in immunology.

[6]  Calvin Cohen,et al.  Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease , 1998, The Lancet.

[7]  C. Smith,et al.  Fas ligand mediates activation-induced cell death in human T lymphocytes , 1995, The Journal of experimental medicine.

[8]  R. Detels,et al.  T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. , 1989, Clinical immunology and immunopathology.

[9]  J. Montaner,et al.  Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. , 1999, AIDS.

[10]  B. Korant,et al.  Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Torres-Roca,et al.  Interleukin-1β Converting Enzyme–like Protease Involvement in Fas-induced and Activation-induced Peripheral Blood T Cell Apoptosis in HIV Infection. TNF-related Apoptosis-inducing Ligand Can Mediate Activation-induced T Cell Death in HIV Infection , 1997, The Journal of experimental medicine.

[12]  C Haanen,et al.  A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. , 1995, Journal of immunological methods.

[13]  J. Tschopp,et al.  Dynamic correlation of apoptosis and immune activation during treatment of HIV infection , 1999, Cell Death and Differentiation.

[14]  V. Miller.  Resistance to Protease Inhibitors , 2001 .

[15]  A. Tomasselli,et al.  Actin, troponin C, Alzheimer amyloid precursor protein and pro-interleukin 1 beta as substrates of the protease from human immunodeficiency virus. , 1991, The Journal of biological chemistry.

[16]  D. Schake.  Pharmazeutische Betreuung von HIV‐Patienten: Wie sollte der Apotheker die Therapie unterstützend begleiten? , 2001 .

[17]  M. Lederman,et al.  In vivo analysis of Fas/FasL interactions in HIV-infected patients. , 1998, The Journal of clinical investigation.

[18]  D. Baltimore,et al.  HIV-1 Directly Kills CD4+ T Cells by a Fas-independent Mechanism , 1998, The Journal of experimental medicine.

[19]  J. Leonard,et al.  Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. , 1998, The Journal of infectious diseases.

[20]  D. Cooper,et al.  CD8+ lymphocyte responses to antiretroviral therapy of HIV infection. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[21]  D. Dockrell.  Apoptotic cell death in the pathogenesis of infectious diseases. , 2001, The Journal of infection.

[22]  C. Payá,et al.  Macrophage-dependent Apoptosis of CD4+ T Lymphocytes from HIV-infected Individuals Is Mediated by FasL and Tumor Necrosis Factor , 1997, The Journal of experimental medicine.

[23]  J Leibowitch,et al.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. , 1997, Science.

[24]  Yoshiyuki Kuchino,et al.  Caspase-independent programmed cell death with necrotic morphology , 1999, Cell Death and Differentiation.

[25]  S. Levitz.  Improvement in CD4+ cell counts despite persistently detectable HIV load. , 1998, The New England journal of medicine.

[26]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[27]  I. McGilveray,et al.  Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patients. , 1993, British Journal of Clinical Pharmacology.

[28]  L. Montagnier,et al.  Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. , 1996, Journal of immunology.

[29]  R. Detels,et al.  Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. , 1993, Journal of acquired immune deficiency syndromes.

[30]  D. Ho,et al.  A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. , 1995, The New England journal of medicine.

[31]  M. Lederman,et al.  CD4+-T-cell counts, spontaneous apoptosis, and Fas expression in peripheral blood mononuclear cells obtained from human immunodeficiency virus type 1-infected subjects , 1997, Clinical and diagnostic laboratory immunology.

[32]  Margot Thome,et al.  Inhibition of death receptor signals by cellular FLIP , 1997, Nature.

[33]  A. Badley,et al.  Effect of cessation of highly active antiretroviral therapy during a discordant response: implications for scheduled therapeutic interruptions. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  J. Konvalinka,et al.  An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity , 1995, Journal of virology.

[35]  R. Ogden,et al.  Comparative CD4 T-Cell Responses of Reverse Transcriptase Inhibitor Therapy With or Without Nelfinavir Matched for Viral Exposure , 2001, HIV Clinical Trials.

[36]  M. Kazatchkine,et al.  Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease , 1998, AIDS.

[37]  H. Handa,et al.  Development of HIV-1 protease expression methods using the T7 phage promoter system , 1997, Applied Microbiology and Biotechnology.

[38]  H. Greenberg,et al.  Studies of the role for NSP4 in the pathogenesis of homologous murine rotavirus diarrhea. , 1998, The Journal of infectious diseases.

[39]  P. Krammer,et al.  Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) , 1995, Nature.

[40]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[41]  M. Lederman,et al.  Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. , 1998, The Journal of infectious diseases.

[42]  Amalio Telenti,et al.  CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART) , 1998, The Lancet.

[43]  R M Zinkernagel,et al.  An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  T. Merigan,et al.  Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. , 1996, The New England journal of medicine.

[45]  M. Peter,et al.  The Role of APO‐1‐Mediated Apoptosis in the Immune System , 1994, Immunological reviews.